Last checked at 
(Alliance News) - Vaccines against new coronavirus variants should be ready by October, the team behind the Oxford University/AstraZeneca PLC jab has said.
In a media briefing hosted by AstraZeneca, Andrew Pollard, director of the Oxford Vaccine Group, said work on designing a new vaccine could be completed rapidly.
It comes after studies have shown that variants of coronavirus with the worrying E484K mutation could make vaccines less effective, though they are still expected to offer good protection against illness and severe disease.
The mutation is found in the South African variant of the virus, which has prompted surge-testing in eight postcode areas of England where community transmission is feared.
It has also been detected in Bristol in the variant first identified in Kent, and in Liverpool in a new variant of the original pandemic strain.
Pollard said: "I think the actual work on designing a new vaccine is very, very quick because it's essentially just switching out the genetic sequence for the spike protein, for the updated variants.
"And then there's manufacturing to do and then a small-scale study.
"So all of that can be completed in a very short period of time, and the autumn is really the timing for having new vaccines available for use rather than for having the clinical trials run."
Mene Pangalos, executive vice president of biopharmaceuticals research and development at AstraZeneca, said: "Our ambition is to be ready for the next round of immunisations that may be necessary as we go into next winter. That's what we're aiming for."
He continued: "We're very much aiming to try and have something ready by the autumn. So, this year."
Pollard said it is likely that clinical trials on new vaccines for dealing with the variants of Covid-19 will involve "hundreds" of people at the most.
"That's a discussion which is ongoing with regulators about exactly what the data package is that they would need," he said.
"The reason why it's such a small number is because, with an updated vaccine, the question is whether immune responses still look the same but against the new variants as they emerge.
"We don't need to run studies on a large scale to prove efficacy. And so that's why they're much quicker and much smaller to conduct."
Pollard also told the briefing that social distancing needs to continue for now, despite Oxford's analysis showing a substantial effect on transmission.
Earlier, he said vaccines in general should still protect against severe disease.
"I think one of the things that we know about these new variants is that they are making changes that allow them to avoid human immune responses so that they can still transmit," he told BBC Breakfast.
"So that does mean that it's likely over time that the virus will find ways of adapting and continue to pass between people despite natural infection and immunity after that or from the vaccines.
"That doesn't mean that we won't still have protection against severe disease, because there's lots of different ways in which our immune system fights the virus – it is much more about the virus being able to continue to survive, rather than for it to cause harm to us."
In a round of broadcast interviews on Wednesday, Health Secretary Matt Hancock said data from Oxford showing its vaccine could substantially cut transmission and "will help us all to get out of this pandemic".
He hailed the new analysis as "absolutely superb" after results showed the jab offers 76% protection up to three months after the first dose and could reduce transmission.
Cutting transmission is the key to lifting the most severe restrictions of lockdown more quickly and means infection levels could come down faster than they would otherwise.
Hancock told BBC Breakfast: "We know from earlier trials that the vaccines are safe and effective at protecting the individual.
"We now know that the Oxford vaccine also reduces transmission and that will help us all to get out of this pandemic, frankly, which is why it is such good news that we should welcome."
Hancock told Times Radio that the number of people in hospital is coming down and deaths will drop.
He said the Oxford data means "we can have a high degree of confidence that that will come down quickly".
He also said data showing that delaying the second dose of the vaccine by up to 12 weeks could increase its efficacy "categorically" supports the government's strategy of stretching the time limit between doses.
"This Oxford report is very good news, it backs the strategy that we've taken and it shows the world that the Oxford vaccine works effectively," he told Sky News.
Shares in Astra were down 1.0% at 7,312.00 pence in London on Wednesday afternoon.
source: PA
Copyright 2021 Alliance News Limited. All Rights Reserved.
